| Literature DB >> 27228013 |
Ana Stevanovic1, Rolf Rossaint1, Michael Veldeman1,2, Federico Bilotta3, Mark Coburn1.
Abstract
BACKGROUND: Awake craniotomy (AC) renders an expanded role in functional neurosurgery. Yet, evidence for optimal anaesthesia management remains limited. We aimed to summarise the latest clinical evidence of AC anaesthesia management and explore the relationship of AC failures on the used anaesthesia techniques.Entities:
Mesh:
Year: 2016 PMID: 27228013 PMCID: PMC4882028 DOI: 10.1371/journal.pone.0156448
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study flow diagram.
Study characteristics.
| Study | Study design | Recruitment period | Sample Size of AC patients | Different AC groups? | Aim /endpoint | Main findings |
|---|---|---|---|---|---|---|
| Abdou 2010 [ | CS (prospective, 1 centre) | NK | 28 | No | To evaluate the clinical efficiency of a mixture of ketamine and propofol called "ketofol"-based sedation procedure for AC. | Conscious sedation during AC using "ketofol" infusion mixture in 1:1 ratio was safe and efficient with minor haemodynamic and respiratory events and rapid smooth recovery profile. |
| Ali 2009 [ | PS (1 centre) | 1/2007-11/2008 | 20 | No | To compare AC technique with GA for excision of low-grade glioma involving eloquent cortex. | AC is a relatively safe procedure with minimal morbidity and does not require a sophisticated technology. Compared to GA, tumour excision in eloquent areas is safer with AC. |
| Amorim 2008 [ | CS (1 centre) | 2001–2004 | 12 | No | To assess the safety and effectiveness of AC in regard to the resection size and postoperative neurological outcome. | Gross total resection was achieved in 66% and only one patient experienced permanent neurological dysfunction postoperatively. |
| Andersen 2010 [ | CS (1 centre) | 5/2004–3/2009 | 44 | No | To retrospectively evaluate the safety of AC in the first AC cases of one institution. | AC was well tolerated and implied several advantages. |
| Beez 2013 [ | PS (5 centres) | 2010–2011 | 105 | Yes (multi-centre trial) | To evaluate pain and discomfort during the awake phase of AC. | AC was well tolerated with low pain and anxiety levels. Female and younger patients experience higher anxiety levels. Discomfort resulted from head fixation or positioning on the operating table. |
| Bilotta 2014 [ | CS (prospective, 1 centre) | 2013 | 20 | No | To describe the experience using a language testing work-up for patients with or at risk for language disturbances undergoing AC. | Broca´s area was identified in 15 patients, in all cases by counting arrest and in 12 cases by naming arrest. This approach allows a systematic evaluation of language function status during AC, even when a neuropsychologist or speech therapist is not involved in the operation crew. |
| Boetto 2015 [ | PS (1 centre) | 1/2009-1/2014 | 374 | No | To analyse the incidence, risk factors and consequences of intraoperative seizures during AC without ECoG. | AC was performed safely and reliable without ECoG. There was a low rate of intraoperative seizures, even in patients with intractable seizure history. |
| Cai 2013 [ | CS (1 centre) | 11/2008-08/2011 | 17 | No | To describe the experience with an oesophageal naso-pharyngeal tube in asleep-awake-asleep anaesthesia. | In all 17 patients the naso-pharyngeal tube was easy to place and well tolerated. During the awake period no excess sedation, lack of cooperation, or hypoxia was recorded. |
| Chacko 2013 [ | RS (1 centre) | 2002–2010 | 67 | No | To describe the experience in 67 consecutive ACs for the excision of tumours located in or around eloquent areas, regarding intraoperative and postoperative deficits. | AC with electro cortical stimulation for eloquent area tumours enables removal of a large tumour volume with good functional outcome. There were no anaesthesiological complications and intraoperative seizures were successfully ceased with cold saline irrigation and anticonvulsants. |
| Chaki 2014 [ | PS (1 centre) | 01/2011-06/2013 | 53 | No | To elucidate the efficacy and safety of a mixture of lidocaine and ropivacaine for scalp nerve block. | Mixture of lidocaine and ropivacaine for scalp nerve blocks in AC is safe and effective. Despite large amounts of the two administered local anaesthetics, the blood level remained under half of the known toxic level for both of them. |
| Conte 2013 [ | PS (1 centre) | 04/2009-05/2010 | 27 | No | To assess if BIS monitoring shortens patient´s awakening and predicts recovery of consciousness in order to establish reliable brain mapping. | Higher BIS values are associated with shorter awakening times during asleep-awake craniotomies. The return of BIS values to pre-induction values was associated with patient´s capability to perform intraoperative language testing. |
| Deras 2012 [ | PS (1 centre) | 01/2008-11/2010 | 140 | No | To assess the efficacy (feasibility and timing of the awake phase) and safety (occurrence of adverse events) of an SAS protocol with controlled ventilation during the asleep phase. | The SAS protocol was feasible and relatively safe, despite one case of pulmonary aspiration (without sequel) and 31.8% of difficult oral intubation respectively 14.8% for laryngeal mask insertion. |
| Garavaglia 2014 [ | CS (prospective, 1 centre) | 03-12/2012 | 10 | No | To assess the anaesthetic technique based on SNB and Dexmedetomidine without airway manipulation in high risk patients. | All patients underwent successful AC, intraoperative mapping, and tumour resection with adequate sedation. Dexmedetomidine in combination with RSNB enables an effective and safe anaesthetic technique for AC. |
| Gonen 2014 [ | RS (1 centre) | 01/2010-05/2012 | 137 | 4 groups, retrospectively built depending on tumour location | To evaluate the association between tumour localization (particularly SMA) and IDH1 mutation status, and the occurrence of intraoperative seizures during AC. | Intraoperative seizures were significantly more frequent in patients with tumours located in the SMA region and a history of seizure. |
| Grossman 2007 [ | PS (1 centre) | NK | 40 | No | To evaluate the effect of wound infiltration and a single dose of metamizole against postoperative pain after AC. | RSNB and local infiltrations in combination with metamizole may provide an effective pain control in AC patients. |
| Grossman 2013 [ | RS (1 centre) | 2003–2010 | 424 | 2 groups retrospectively built (334 young and 90 elderly >65years) | To compare surgical outcome between younger and elderly patients undergoing AC. | There was no difference between the groups regarding rate of mortality, or complications. However age was associated with increased length of stay. Maximal extent of HGG tumour resection was associated with prolonged survival rate. |
| Gupta 2007 [ | RCT (1 centre) | 1/2001-5/2003 | 26 | 1 AC group | To compare the efficacy of AC versus GA for patients with tumours in eloquent, in regard to new neurological dysfunctions and the extent of tumour resection. | Except for the surgery time, they did not find any significant statistical difference between the groups. |
| Hansen 2013 [ | PS (1 centre) | 05/2006-03/2012 | 50 procedures in 47 patients | No | To report a novel approach of AC based on cranial nerve block, permanent presence of a contact person, psychological guidance and therapeutic communication. | No patient required sedation, only two-thirds of the patients requested remifentanil with a mean of 96 µg before the end of tumour resection. Hemodynamic reactions were mainly seen during nerve blockades and neurological testing. This approach was considered as “awake-awake-awake-technique” |
| Hervey-Jumper 2015 [ | RS (1 centre) | 1997–2014 | 611 | No | To analyse a single surgeon’s experience and the evolving methodology of awake language and sensorimotor mapping for glioma surgery. | AC can be safely performed with few complications and a low failure rate, regardless of ASA, Mallampati score, BMI, smoking, psychiatric history, seizure history, or tumour mass effect. Incidence of seizures was associated with preoperative seizure history and tumour location. There was no statistical difference between the used sedation technique and intraoperative seizures, LMA use, kind of tumour, BMI or AC failures. |
| Ilmberger 2008 [ | PS (1 centre) | 1991–2005 | 153 procedures in 149 patients | No | To evaluate pre- and postoperative language function using a standardised neurolinguistic test battery, after AC for tumours in eloquent areas. | AC is a safe and economic, well tolerated procedure. Every attempt should be undertaken to preserve language-relevant areas intraoperatively. New postoperative deficits were resolved in the majority of patients. Patients with suboptimal preoperative naming capacities are at higher risk for early postoperative language impairment. |
| Jadavji-Mithani 2015 [ | Pseudo-RCT (1 centre) | 05-08/2012 and 05-08/2013 | 29 | 2 groups (major key music and minor key music) | To assess if music is beneficial for AC patients. | Overall, listening to music selections was beneficial for the patients. Adverse events were independent of the kind of music. |
| Kim 2009 [ | RS (1 centre) | 1/1993-372006 | 309 procedures in 289 patients | No | To analyse the correlation of intraoperative cortical mapping and postoperative neurological outcomes. | Negative mapping of eloquent areas enables surgical resection with a low rate of neurological deficits. Tumour proximity to functional cortex bears an increased risk for postoperative neurological deficits. |
| Li 2015 [ | PS (1 centre) | 01/2003-01/2012 | 91 | No | To investigate the method and significance of direct electrical stimulation (DES) to the brain mapping of language functions during glioma surgery in Chinese patients | DES was found to be a reliable non-invasive method for cerebral functional area positioning and maximal safe resection of gliomas in Chinese patients. |
| Lobo 2007 [ | CS (1 centre) | NK | 8 | No | To describe an SAS technique with propofol and remifentanil infusion, pharmacokinetic simulation to predict the effect-site concentrations and to modulate the infusion rates of both drugs, and bispectral index (BIS) monitoring. | A significant correlation was found between BIS and predicted effect-site concentrations of propofol (r2 = 0.547, P<0.001) and remifentanil (r2 = 0.533, P<0.001). Intraoperative awakening was very fast (3 minutes). |
| Low 2007 [ | RS (1 centre) | 7/2003-8/2006 | 20 | No | To examine the safety and effectiveness of AC under local anaesthesia and MAC sedation for resection of tumours involving eloquent cortex. | MAC sedation in combination with frameless computer stereotactic guidance is a safe technique, which enables maximal resection of lesions in close relationship to eloquent cortex and has a low risk of neurological deficit. |
| McNicholas 2014 [ | CS (2 centres) | 1 year (not further specified) | 42 (Rome n = 28, Chicago n = 14) | No | To describe transient postoperative facial nerve palsy as a complication of auriculotemporal nerve blockade in AC. | Seven out of 42 patients developed transient postoperative facial nerve palsy. The technique may need to be refined to avoid such complications. |
| Nossek 2013 [ | RS (1 centre) | 2003–2010 | 424 | 2 groups were retrospectively built. (AC failure n = 397 patients vs. n = 27 not failure patients) | To assess the prevalence of AC failure (general anaesthesia required or adequate mapping failed). | 27 (6.4%) AC failures occurred with multiple reasons: lack of communication (4.2%) and intraoperative seizures (2.1%). Preoperative dysphasia and treatment with phenytoin were related to failure. The majority of AC failures were preventable by adequate patient selection and by avoiding side effects of drugs administered during intervention. |
| Nossek 2013 [ | RS (1 centre) | 2003–2011 | 477 | 2 groups were retrospectively built. (seizure n = 60 + non-seizure n = 417) | To analyse the incidence, risk factors, and consequences of seizures during asleep-awake-asleep AC. | 60 patients (12.6%) of 477 patients with complete records experienced intraoperative seizures in which 2.3% failed AC procedure. Seizures are more frequent in younger patients, in patients with frontal lobe involvement, and in patients with a history of seizures. Seizures are associated with a short-term motor deterioration and a longer hospitalisation. The perioperative team should be prepared to treat intraoperative seizures. |
| Olsen 2008 [ | CS (1 centre) | 5/2004-2/2006 | 25 | No | To present a new ‘asleep–awake’ technique for tumour resection. | The presented method was well tolerated by the patients and allowed modification of the surgery according to the live intraoperative mapping results. Omitting a second asleep phase at the end of surgery seems to be more advantageous compared to the SAS technique. |
| Ouyang 2013 [ | RS (1 centre) | 01/2005-12/2010 | 386 | 2 groups retrospectively built. (midline-shift n = 103 + no midline-shift n = 283) | To identify if patients with midline shift, and more cerebral oedema would suffer from a higher incidence of PONV. | There was no correlation between midline shift and postoperative nausea or pain in AC. |
| Ouyang 2013 [ | RS (1 centre) | 01/2005-12/2010 | 415 | 2 groups were retrospectively built. (benign tumour n = 115 + malignant tumour n = 300) | To compare the incidence of postoperative nausea between benign and malignant brain tumours. | There was no difference in the incidence of nausea between benign and malignant brain tumours, but patients with benign tumours showed a higher pain score postoperatively. |
| Pereira 2008 [ | CS (prospective, 1 centre) | 1998–2007 | 79 | 2 groups (Group A without multidisciplinary team 1998-7/2004 n = 33, group B with multidisciplinary team 8/2004-2008 n = 46) | To evaluate the safety and efficacy of fully AC for the resection of primary supratentorial brain tumours near or in eloquent brain areas. Furthermore, to assess the impact of previous surgery and treatment modalities on the outcome. | AC is a safe and effective procedure and in a multidisciplinary context is associated with greater clinical and physiological monitoring. The outcome was not influenced by surgical history of AC. |
| Peruzzi 2011 [ | RS (2 centres) | 1/2006-12/2008 | 22 procedures in 20 patients | 1 AC group | To compare the hospital length of stay, hospital cost, perioperative morbidity, and postoperative outcome between patients undergoing awake glioma surgery vs. surgery under GA. | There were no significant differences in the patient outcomes, but the hospital length of stay and hospital costs were significantly reduced in the AC group. |
| Pinsker 2007 [ | RS (1 centre) | 1/1998-12/2002 | 55 procedures in 52 patients | No | To analyse the safety and maximal extension of tumour resection with AC in the eloquent brain area. | AC enables a more radical resection of tumours in eloquent brain areas, otherwise considered as inoperable. |
| Rajan 2013 [ | RS (1 centre) | 2007–2010 | 101 | No | To assess if AC (asleep-awake-asleep) with dexmedetomidine/ propofol/ fentanyl has acceptable perioperative outcomes compared to general anaesthesia. | Temporary episodes of desaturation and hypercapnia occurred more often in the AC group. Blood pressure was lower in the AC group during application of head clamp pins and emergence and the AC group required less vasopressors intraoperatively. AC provides adequate sedation, analgesia and a smooth wake-up during the period of neurological monitoring with stable haemodynamic and acceptable respiratory parameters compared to general anaesthesia. AC group showed less PONV and pain postoperatively. |
| Rughani 2011 [ | CS (1 centre) | 01/2007-07/2009 | 25 | No | Description of a new anaesthesiological protocol and patient outcomes for the first patients undergoing AC surgery in this institution. | Implementation of the new anaesthesiological approach was successful, with a low operative morbidity and rate of anaesthesia complications, short surgery time, and well tolerance by the patients. |
| Sacko 2010 [ | PS (1 centre) | 01/2002-12/2007 | 214 | No | To assess the safety and effectiveness of AC in comparison to GA for lesions close to the eloquent cortex. | AC patients showed a significantly better neurological outcome, faster discharge times and an uneventful surgery. |
| Sanus 2015 [ | CS (1 centre) | 2010–2013 | 25 | No | The safety and effectiveness of AC in 25 patients should be described. | AC in selected patients is an effective, safe and practical procedure, which is accompanied with a short hospital and ICU length of stay. |
| See 2007 [ | CS (1 centre) | 7/2004-6/2006 | 17 | No | To analyse the individual anaesthetic management, intraoperative complications and postoperative outcome of patients undergoing AC. | AC was well tolerated and showed a low rate of complications, with the benefit of maximal tumour excision and a potentially better patient outcome. |
| Serletis 2007 [ | PS (1 centre) | 1/1991-7/2006 | 511 | 2 groups (eloquent cortex AC n = 511, non-eloquent cortex AC n = 99) | To elucidate the outcomes and potential advantages associated with AC for supratentorial tumour resection, treated by one neurosurgeon. | AC is safe, practical, and effective during resection of supratentorial lesions of diverse pathological range and location. |
| Shen 2013 [ | RCT (1 centre) | 01-11/2012 | 30 | 2 groups (propofol vs. dexmedetomidine) | To compare the efficacy and safety of dexmedetomidine versus propofol for conscious sedation in AC and to determine the arousal time until awake phase after asleep phase. | Arousal time was longer in the propofol group. Surgeon´s satisfaction was higher in the dexmedetomidine group. There was no difference in patients´ satisfaction, adverse outcomes and quality of revival. Both anaesthetics can be effectively and safely used for conscious sedation in AC. |
| Shinoura 2013 [ | RS (1 centre) | 2003–2013 | 102 | No | To analyse associated factors for worsened paresis after AC for brain lesions located within or near the primary motor area. | Preoperative motor deficits, closeness to the motor area, partial resection, AC failure and intraoperative complications are associated risk factors for postoperative worsening of paresis. |
| Sinha 2007 [ | RS (1 centre) | until 2005 | 42 | 2 groups (BIS n = 16, no BIS n = 26) | To evaluate the AC procedure in regard to complications during surgery. | With the use of advanced monitoring (BIS) and newer anaesthetics, AC was a relatively safe procedure with an acceptable rate of complications. |
| Sokhal 2015 [ | RS (1 centre) | 2001–2010 | 54 | No | To analyse the anaesthetic management and perioperative complications in patients undergoing AC. | Appropriate patient selection and careful anaesthesia management are the keys to the success of AC. ‘Conscious sedation’ was performed successfully with fentanyl, propofol and dexmedetomidine. Patients treated with propofol showed fewer incidences of intraoperative seizures. |
| Souter 2007 [ | CS (1 centre) | NK | 6 | No | To describe the experience with dexmedetomidine as the principle sedative agent on functional cortical mapping and ECoG recording during AC for excision of epileptogenic foci. | Dexmedetomidine as a single sedative was successfully used for AC including motor mapping, when coupled with RSNB and relatively small doses of fentanyl. |
| Wrede 2011 [ | PS (1 centre) | 4 years | 48 procedures in 46 patients | 1 AC group | To objectively assess the patients`experience with AC compared to GA for brain tumours by using a formal questionnaire. | A good patient acceptance of AC procedures for tumours in eloquent regions could be verified in this study. |
| Zhang 2008 [ | RS (1 centre) | 3/2005-5/2006 | 30 | 3 groups (1. positive mapping, 2. negative mapping, 3. aborted mapping) | To evaluate surgical resection of gliomas in eloquent brain regions with intraoperative cortical stimulation mapping under AC. | AC with cortical mapping is an accurate and safe approach to identify language cortex and enables extensive tumour excision while preserving normal language function and minimizing the risk of postoperative language deficits. |
AC, awake craniotomy; BIS, bispectral index; CS, case study; ECoG, electrocorticography GA, general anaesthesia; IDH1, isocitrate dehydrogenase 1; n =, specified number of patients; PONV, postoperative nausea and vomiting; PS, prospective observational study; RA, regional anaesthesia; RCT, randomised controlled trial; RS, retrospective study; RSNB, regional scalp nerve block; SMA, supplementary motor area; TIVA, total intravenous anaesthesia.
Anaesthesia characteristics part 1.
| Study | Anaesthesia technique | Premedication/ additional medication | Local anaesthesia (Pins and dura) | RSNB | Drugs used for RSNB |
|---|---|---|---|---|---|
| Abdou 2010 [ | MAC | Midazolam 15 μg kg-1, ondansetron 8 mg, dexamethasone 8 mg, phenytoin 250 mg and mannitol 0.5g kg-1 i.v. | Yes | NK | NK |
| Ali 2009 [ | MAC | Clonidine 4 μg kg-1, ranitidine 50 mg and metoclopramide 10 mg, dexamethasone 8 mg, phenytoin 5 mg kg-1, diclofenac, and acetaminophen 1 g i.v. half an hour before surgery. | Yes | Yes | Mixture of bupivacaine 0.25% and lidocaine 1% with 1:200,000 epinephrine (2–3 ml at each infiltration site). |
| Amorim 2008 [ | MAC | NK | Yes | Yes | Lidocaine 0.5%, bupivacaine 0.25% with epinephrine 1:200,000 |
| Andersen 2010 [ | SA | Midazolam (n = 2 patients), mannitol (n = 37) | Yes | Yes | NK |
| Beez 2013 [ | 97 patients SAS, 8 patients SA | NK | Yes | Yes | NK |
| Bilotta 2014 [ | MAC | 1–1.5 mg midazolam | Yes | Yes | Ropivacaine 0.75% injected on 4 sites in each side of the head (8 injections in total): 2.5 to 5 ml. The dose depends on the site and on the body weight of the patients. (In total 20-40ml ropivacaine) |
| Boetto 2015 [ | SAS | 4mg ondansetron, 400mg cimetidine, 1g acetaminophen. Anticonvulsant drugs were continued in patients with seizure history. | Yes | Yes | 20 ml lidocaine 2% with epinephrine |
| Cai 2013 [ | SAS | NK | NK | NK | NK |
| Chacko 2013 [ | MAC | NK | Yes | Yes | A mixture of bupivacaine (1–1.5mg kg-1) and lidocaine (3–4 mg kg-1) with epinephrine concentration of 5μg ml-1 |
| Chaki 2014 [ | SAS | Betamethasone (4 mg) and famotidine (20 mg) as PONV prophylaxis | Yes | Yes | Lidocaine 2% and ropivacaine 0.75% with epinephrine at 1:200,000 (5μg ml-1) |
| Conte 2013 [ | SA | Midazolam 0.07–0.08 mg kg-1 i.m. and atropine 0.5 mg i.m. 30–60 min. before surgery. Antiemetic: metoclopramide chloridrate 10 mg i.v. or dolasetron 5 mg i.v., anticonvulsant medication in all patients | Yes | Yes | Mixture of ropivacaine 1%, mepivacaine 1%, epinephrine 1:200,000, and lidocaine 2%. |
| Deras 2012 [ | SAS | 4mg ondansetron, 400mg cimetidine, 1g acetaminophen | Yes | NK | NA |
| Garavaglia 2014 [ | MAC | 4mg ondansetron i.v. | Yes | Yes | 0,375% bupivacaine without epinephrine (2-3ml at each injection site) |
| Gonen 2014 [ | MAC | Midazolam 1-2mg and 50–100μg fentanyl | Yes | Yes | NK |
| Grossman 2007 [ | MAC | Clonidine 2–3 μg kg-1 one hour before surgery. At the end of surgery: Additional lidocaine 2% and epinephrine 1:200,000 were infiltrated to the scalp and dura mater and the patients received metamizole 1g intramuscularly/ respectively diclofenac 75 mg. | Yes | Yes | Bupivacaine 0.5% and lidocaine 2% in a 1:1 mixture. |
| Grossman 2013 [ | MAC | Midazolam 1-2mg and 50-100g fentanyl | Yes | Yes | NK |
| Gupta 2007 [ | MAC | No | Yes | Yes | Bupivacaine 0.5% with epinephrine 1:200,000 (2.5ml at each injection site), maximum 225 mg bupivacaine |
| Hansen 2013 [ | AAA | 8 mg dexamethasone | Yes | Yes | 28 ml of ropivacaine 0.75% with epinephrine 1:200,000 |
| Hervey-Jumper 2015 [ | MAC | 50μg fentanyl, 1-2mg midazolam, antiemetic drugs: ondansetron and scopolamine | Yes | Yes | 1:1 mixture of 1% lidocaine with 1:100,000 epinephrine, 0.5% bupivacaine, plus 4.5 ml of 8.4% sodium bicarbonate |
| Ilmberger 2008 [ | MAC | 750 mg phenytoin | NK | Yes | 60–80 ml bupivacaine 0.25% |
| Jadavji-Mithani 2015 [ | MAC | Midazolam (dosage NK) only in 14 patients, who received propofol + remifentanil anaesthesia | Yes | No | NA |
| Kim 2009 [ | SAS | 4 mg ondansetron, 20 mg famotidine, and 10 mg metoclopramide preoperative. | Yes | Yes | 40 ml ropivacaine 0.5% with epinephrine 1:200,000 |
| Li 2015 [ | SAS | NK | Yes | Yes | Bupivacaine or ropivacaine (dosage NK) |
| Lobo 2007 [ | SAS | Midazolam 2.2 ± 0.3mg i.v. Dexamethasone 10 mg and ondansetron 4mg i.v. were given before incision. Phenytoin 250 to 500 mg i.v. during surgery | NK | Yes | Up to 40 ml ropivacaine 0.75% with epinephrine 1:200,000 |
| Low 2007 [ | MAC | Intravenous mannitol, dexamethasone, antibiotics and anticonvulsants were administered prior to skin incision. | Yes | Yes | Bupivicaine 0.5% and epinephrine (1:200,000) |
| McNicholas 2014 [ | MAC | NK | Yes | Yes | Rome: n = 28, 40ml ropivacaine 0,75%, Chicago: n = 1, 20ml bupivacaine 0.25%with epinephrine 1:200,000, the others, n = 13, 6 ml of 1% tetracaine and 30 ml lidocaine 1% with epinephrine 1:100,000 |
| Nossek 2013 [ | MAC | Anticonvulsant medication in all patients, midazolam 1-2mg and 50-100g fentanyl | Yes | Yes | NK |
| Nossek 2013 [ | MAC | Anticonvulsant medication in all patients, midazolam 1-2mg and 50-100g fentanyl | Yes | Yes | NK |
| Olsen 2008 [ | SA | Midazolam n = 4. Paracetamol 1-2mg i.v., dehydrobenzperidol 0.6 mg, ondansetron 4 mg, dexamethasone 8 mg, mannitol n = 22. Phenytoin loading dose n = 24 | Yes | Yes | 15-20ml bupivacaine 5mg ml-1 + 5μg ml-1 epinephrine |
| Ouyang 2013 [ | SAS | Dexamethasone 10–20 mg i.v., mannitol 1–2 g kg-1 intraoperative, ondansetron 4mg and/ or metoclopramide 10mg | NK (local anaesthesia mentioned, but not specified) | NK (local anaesthesia mentioned, but not specified) | NK |
| Ouyang 2013 [ | SAS | Dexamethasone 10–20 mg i.v., mannitol 1–2 g kg-1 intraoperative, ondansetron 4mg and/ or metoclopramide 10mg | NK (local anaesthesia mentioned, but not specified) | NK (local anaesthesia mentioned, but not specified) | NK |
| Pereira 2008 [ | MAC | Additional naloxone in some patients for opioid revision before mapping. | Yes | Yes | Bupivacaine 0.07% and epinephrine 1:800,000 (whole hemi cranium) |
| Peruzzi 2011 [ | MAC | NK | Yes | No | NA |
| Pinsker 2007 [ | MAC | Antiepileptic drug. | NK | Yes | 0.375% bupivacaine |
| Rajan 2013 [ | SAS | NK | Yes | No | NA |
| Rughani 2011 [ | SAS | Midazolam 1-2mg i.v. and 50–200μg fentanyl, 10 min. before entering surgery room; 10 mg dexamethasone, 4-8mg ondansetron i.v.; mannitol 12.5 to 100g only if brain swelling; phenytoin 18mg kg-1 for each patient with additional 500mg phenytoin to already treated patients. | Yes | Yes | 40ml 0.25% bupivacaine |
| Sacko 2010 [ | MAC | Levetiracetam, 500 mg, methylprednisolone 1 mg kg-1 | Yes | Yes | Lidocaine 1% with epinephrine 1:100 000 |
| Sanus 2015 [ | SAS | Midazolam 30–50 μg kg-1 i.v., anticonvulsants and corticosteroids immediately before surgery | Yes | No | NA |
| See 2007 [ | MAC | Midazolam (n = 5), anticonvulsant therapy and dexamethasone were continued perioperatively. | Yes | Yes | 0.75% lidocaine (1:200,000 adrenaline) with or without 0.25% bupivacaine |
| Serletis 2007 [ | MAC | Anticonvulsant and corticosteroid. | Yes | Yes | 0.25% bupivacaine |
| Shen 2013 [ | SAS | No midazolam | Yes | Yes | 60ml ropivacaine 0.25% including local infiltration anaesthesia (pins and scalp) |
| Shinoura 2013 [ | SAS | NK | Yes | Yes | Lidocaine 1% with epinephrine and 0.75% anapain |
| Sinha 2007 [ | MAC | No midazolam. Clonidine 4 μg kg-1, ranitidine, atenolol 25mg and double the dose of anticonvulsants orally in the morning. Ondansetron 4mg before and at the end of surgery. Haloperidol 2.5-5mg i.v. at induction. Corticosteroids, anti-epileptic drugs and mannitol were applied additionally. | Yes | Yes | Bupivacaine 0.25% and lidocaine 1% with 1:200,000 epinephrine (2–5 ml at each site). Mean 34.3ml, range [28-66ml] |
| Sokhal 2015 [ | MAC | No midazolam, preoperative application of corticosteroids (dosage NK) and mannitol at surgery start. | Yes | Yes | At each site, 3-5ml bupivacaine 0.25–0.5% |
| Souter 2007 [ | SAS (n = 2), MAC (n = 4) | No midazolam. | Yes | Yes | 35–40 ml lidocaine 1.0% with 1:200,000 epinephrine and bupivacaine 0.25%. |
| Wrede 2011 [ | MAC | NK | Yes | No | NA |
| Zhang 2008 [ | MAC | Only minimal preoperative sedation is described. | Yes | Yes | Ropivacaine 0.5% |
AAA, awake-awake-awake technique; Anaesth., Anaesthesia; Ces, effect-site concentration; i.m., intra muscular; i.v., intravenous; LMA, laryngeal mask airway; min., minutes; n =, specified number of patients; NA, not applicable; NK, Not known as not reported; PONV, postoperative nausea and vomiting; RSNB, Regional selective scalp nerve block; SA, asleep-awake technique; SAS, asleep-awake-asleep technique; TCI, Target controlled infusion; TIVA, total intravenous anaesthesia.
Anaesthesia characteristics part 2.
| Study | SA(S) Management | Dosage SA(S) | MAC /AAA Management | Awake phase | End of surgery | Use of muscle relaxants | Anaesth. depth control | Airway |
|---|---|---|---|---|---|---|---|---|
| Abdou 2010 [ | NA | NA | Propofol 0.5 mg kg-1 h-1 and ketamine 0.5 mg kg-1 h-1 infusion mixture in 1:1 ratio in one syringe, thereafter adapted to the OAA/S score (aim level 3) | No medication | Resumed propofol/ ketamine mixture, and additional fentanyl 1–2μg kg-1 for postoperative analgesia | No | Only clinical with the (OAA/S) score | Nasal cannula (4 l min-1), (spontaneous breathing) |
| Ali 2009 [ | NA | NA | 1. Before RSNB: bolus propofol 50–100 mg and fentanyl 50μg. 2.Continous propofol 1–2 mg kg-1 h-1 and fentanyl 0.5 mg kg-1 h-1. | Continued conscious sedation | Continued conscious sedation | No | No | n = 15 nasal cannula (2–4 l min-1), n = 5 oropharyngeal airway; (spontaneous breathing) |
| Amorim 2008 [ | NA | NA | Midazolam, fentanyl, propofol n = 6; dexmedetomidine 3 mg kg-1 h-1 (over 20 min.), followed by 0.5 mg kg-1 h-1 n = 6 | NK | NK | No | No | Spontaneous breathing |
| Andersen 2010 [ | TIVA (propofol + remifentanil) | NK | NA | Remifentanil n = 37, mean 0.03 [0–0.08] μg kg-1 min-1 | Nothing | No | No | LMA (controlled ventilation), endotracheal tube in one AC patient |
| Beez 2013 [ | TIVA (propofol + remifentanil) | NK | NA | No medication | TIVA (propofol + remifentanil) n = 97 | No | No | LMA (controlled ventilation) |
| Bilotta 2014 [ | NA | NA | Initial bolus of fentanyl 0.5–1μg kg-1, dexmedetomidine, midazolam and remifentanil (clinically adjusted to the patients`need). | No medication | Nothing | No | Only clinical by Richmond agitation sedation score (RASS aim 0/-2) | Oxygen via facemask. (spontaneous breathing) |
| Boetto 2015 [ | TCI-TIVA (propofol + Remifentanil) | TCI: Initial: Propofol 6 μg ml-1 and remifentanil 6 ng ml-1. After dural incision: reduction of propofol to 3 μg ml-1 and remifentanil to 4 ng ml-1. | NA | No medication (LMA removal) | TCI-TIVA, propofol 6–12 μg ml-1 and remifentanil 6–12 ng ml-1 | No | No | LMA (controlled ventilation) for the initial asleep phase, LMA or orotracheal tube with controlled ventilation for the second phase |
| Cai 2013 [ | TCI-TIVA (propofol + Remifentanil) | TCI: Initial: Propofol 3–6 μg ml-1 and remifentanil 3–4 ng ml-1. After dural incision: reduction Ces of propofol to 1 μg ml-1 and remifentanil to 1 ng ml-1. Aim BIS 40–60. | NA | Only remifentanil 1 ng ml-1 | NK | Rocuronium 0.6mg kg-1 | BIS | Oesophageal naso-pharyngeal catheter (controlled ventilation) |
| Chacko 2013 [ | NA | NA | Initial: 50 μg boluses of fentanyl and propofol or dexmedetomidine infusion. Thereafter propofol (1–2mg kg h−1) | No medication | NK (for 1 patient propofol is described) | No | No | 2l min-1 oxygen via nasal cannula (spontaneous breathing) |
| Chaki 2014 [ | TCI-Propofol | TCI: Initial 4.0μg ml-1 propofol. Thereafter reduction to 1.5–3.5μg ml-1 | NA | No medication, if pain: 50 mg flurbiprofen i.v. | TCI-Propofol and reinsertion of LMA | Rocuronium 0.6mg kg-1 | No | LMA (controlled ventilation) |
| Conte 2013 [ | TIVA (propofol + remifentanil) | Initial: Propofol 2.0–2.5 mg kg-1 and remifentanil 0.025–0.1 μg kg-1 min-1. Thereafter: Propofol 5–10 mg kg-1 h-1 and remifentanil 0.05–0.2 μg kg-1 min-1. | NA | Reduced remifentanil 0.025–0.1 μg kg-1 min-1. | Reduced remifentanil 0.025–0.1 μg kg-1 min-1 | No | BIS | LMA (controlled ventilation) |
| Deras 2012 [ | TCI-TIVA (propofol + Remifentanil) | TCI: Initial: Propofol 6 μg ml-1 and remifentanil 6 ng ml-1. After dural incision: reduction of propofol to 3 μg ml-1 and remifentanil to 4 ng ml-1. | NA | No medication (LMA removal) | TCI-TIVA, propofol 6–12 μg ml-1 and remifentanil 6–12 ng ml-1 | No | No | LMA (controlled ventilation) for the initial asleep phase, LMA or orotracheal tube with controlled ventilation for the second phase |
| Garavaglia 2014 [ | NA | NA | Initial: dexmedetomidine 0.5–1μg kg-1 loading dose. Thereafter: 0.3–0.4 μg kg-1 h-1dexmedetomidine supplemented with 50–100μg fentanyl or 0.01–0.015μg kg-1min-1remifentanil and midazolam 1-4mg | No medication | Dexmedetomidine 0.2–1μg kg-1min-1 and 0.005–0.01μg kg-1min-1remifentanil | No | Only clinical by Richmond agitation sedation score (RASS aim 0/-2) | 3l min-1 oxygen via facemask. (spontaneous breathing) |
| Gonen 2014 [ | NA | NA | Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) | No medication | Remifentanil and supplementation with propofol. (Dosage NK) | No | No | 3l min-1 oxygen via nasal cannula. (spontaneous breathing) |
| Grossman 2007 [ | NA | NA | 1. Propofol at an initial dose of 50 μg kg-1 min-1 and remifentanil 0.05 μg kg-1 min-1. 2. Remifentanil reduction to 0.01 μg kg-1 min-1 and propofol adjusted. | No medication | Propofol was resumed with 15 μg kg-1 min-1 and if needed additional remifentanil 0.01 μg kg-1 min-1 was applied (n = 18). | No | No | Nasal cannula (spontaneous breathing) |
| Grossman 2013 [ | NA | NA | Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) | No medication | Remifentanil and supplementation with propofol. (Dosage NK) | No | No | 3l min-1 oxygen via nasal cannula. (spontaneous breathing) |
| Gupta 2007 [ | NA | NA | Initial: Fentanyl 2–3 μg kg-1 and propofol 2–2.5 mg kg-1. Thereafter: additional bolus of fentanyl 1 μg kg-1 (usually every 2h), and continuous propofol 50–100 μg kg-1 min-1. | Reduced dosage of propofol and fentanyl | As at the beginning | No | No | 3l min-1 oxygen via nasal cannula. (spontaneous breathing) |
| Hansen 2013 [ | NA | NA | Remifentanil was only required in 34 patients. Mean dosage 156±100 μg for the whole AC procedure. | Required remifentanil dosage during tumour resection 96±57 μg | Remifentanil was only required in 34 patients. Mean dosage 156±100 μg for the whole AC procedure. | No | BIS | Nasal cannula (spontaneous breathing) |
| Hervey-Jumper 2015 [ | NA | NA. | TIVA (propofol up to 100 μg kg-1 min-1 + remifentanil 0.07–2.0 μg kg-1 hr-1) n = 327, dexmedetomidine up to 1 μg kg-1 min-1+ remifentanil n = 26, adjusted technique using all drugs n = 258 | No medication (LMA removal), remifentanil continued in anxious patients. | TIVA or dexmedetomidine + remifentanil (reinsertion of LMA if indicated) | No | No | Nasal cannula (spontaneous breathing), additionally nasal trumpet if snoring. In high-risk patients n = 8 (high BMI, high tumour mass, high blood loss estimated) LMA. |
| Ilmberger 2008 [ | NA | NA | Continuous propofol (0.5–1.2 mg kg-1) and remifentanil (0.05–0.01 μg kg-1 min-1) | NK | Resuming sedation like at the beginning | No | No | Nasal cannula (spontaneous breathing) |
| Jadavji-Mithani 2015 [ | NA | NA | TIVA (propofol + remifentanil) n = 14, dexmedetomidine n = 15 | No medication | NK | No | No | Nasal cannula or facemask (spontaneous breathing) |
| Kim 2009 [ | TIVA (propofol + remifentanil) | Initial: Propofol 50–100 mg and remifentanil 0.1–0.2 μg kg-1 min-1. Thereafter: ≤ 3% desflurane and remifentanil 0.05–0.2 μg. | NA | LMA removal, if needed: remifentanil 0.02 μg kg-1 min-1 | Dexmedetomidine 0.5–0.7 μg kg-1 h-1 and propofol 25–50 μg kg-1 min-1 and remifentanil 0.02–0.05 μg kg-1 min-1, LMA reinserted. | 50 mg rocuronium (some patients) | No | LMA (controlled ventilation) |
| Li 2015 [ | Propofol | NK | NA | No medication (LMA removed) | Propofol and LMA reinserted | No | No | LMA (controlled ventilation) |
| Lobo 2007 [ | TCI-TIVA (propofol + Remifentanil) | Initial: 1% Propofol-TCI Schneider model 200ml h-1 and remifentanil-TCI, Minto model, 2.5ng ml-1, thereafter: 1 mg ml-1 of propofol and 2 ng ml-1 effect site concentration | NA | TCI-TIVA on low level (LMA removed) | TCI-remifentanil 2.5 ng ml-1and propofol bolus 10mg. LMA if needed 0.05 mg kg-1 morphine | No | BIS | LMA (controlled ventilation) |
| Low 2007 [ | NA | NA | Combination of midazolam, propofol, fentanyl or remifentanil | Reduced dosage | Deep sedation | No | No | Oxygen via facemask (spontaneous breathing) |
| McNicholas 2014 [ | NA | NA | Rom: (n = 28) Initial 1μg kg-1 fentanyl + propofol 0.5mg kg-1. Thereafter propofol 1.6–8.3 μg kg-1 min-1. Chicago: (n = 13) Initial remifentanil (exact dosage NK, but aim 8–12 breaths min-1 + propofol 10–25 μg kg-1 min-1, (n = 1) 2mg midazolam and 100μg fentanyl | No medication | NK | No | No | Oxygen via facemask (spontaneous breathing) |
| Nossek 2013 [ | NA | NA | Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) | No medication | Remifentanil and supplementation with propofol. (Dosage NK) | No | No | 3l min-1 oxygen via nasal cannula. (spontaneous breathing) |
| Nossek 2013 [ | NA | NA | Remifentanil in low dosage and if necessary supplementation with propofol. (Exact dosage NK) | No medication | Remifentanil and supplementation with propofol. (Dosage NK) | No | No | 3l min-1 oxygen via nasal cannula. (spontaneous breathing) |
| Olsen 2008 [ | TIVA (propofol + remifentanil) | Initial: remifentanil 0.7 μg kg-1 min-1, bolus propofol (median 200mg) until loss of eyelid reflex, followed by continuous propofol 0.17 mg kg-1 min-1, thereafter 50% reduction of remifentanil and propofol | NA | Remifentanil 0.3 μg kg-1 min-1 | Nothing | No | No | LMA (controlled ventilation), endotracheal tube in one AC patient |
| Ouyang 2013 [ | TIVA (Propofol + remifentanil + fentanyl) | Initial: Propofol 1–2 mg kg-1, lidocaine (0.5–1.5 mg kg-1 and fentanyl 1–2 μg kg-1. Thereafter: Propofol 100–150 μg kg-1 min-1 and remifentanil 0.05–0.09 μg kg-1 min-1. | NA | No medication | TIVA (Propofol + remifentanil) | No | No | LMA or nasal trumpets (spontaneous breathing) |
| Ouyang 2013 [ | TIVA (Propofol + remifentanil + fentanyl) | Initial: Propofol 1–2 mg kg-1, lidocaine (0.5–1.5 mg kg-1 and fentanyl 1–2 μg kg-1. Thereafter: Propofol 100–150 μg kg-1 min-1 and remifentanil 0.05–0.10 μg kg-1 min-1. | NA | No medication | TIVA (Propofol + remifentanil) | No | No | LMA or nasal trumpets (0,5–1,0 FiO2, spontaneous breathing), during awake phase only 0,21 FiO2. |
| Pereira 2008 [ | NA | NA | Group A (n = 33) 3/1998–2/200,2 bolus titration of propofol and remifentanil or fentanyl, plus midazolam. Group B (n = 46) after 2/2002, only fentanyl (50μg) boluses slowly until the minimum dose of 10 μg kg-1 in the first 1 h, followed by fentanyl 1 μg kg-1 every further hour (n = 43) | Until 2002 no medication, after 2002 adapted fentanyl boluses | After 2002 repeated boluses of fentanyl | No | No | Spontaneous breathing |
| Peruzzi 2011 [ | NA | NA | Initial: dexmedetomidine 0.1–0.7μg kg-1 h-1 and if needed: 0.1mg kg-1 midazolam, thereafter bolus propofol until loss of consciousness, followed by a continuous application of propofol 40–120 μg kg-1 min-1 combined with dexmedetomidine 0.1–0.7μg kg-1 h-1. Sevoflurane 0.5–1% was added, to reduce propofol. BIS aim 50–60. | Only titrated dexmedetomidine infusion and fentanyl 12.5–25 μg if needed for pain | Additional propofol | No | OAA/S and BIS | Oxygen via nasal trumpet, connected to the ventilator (spontaneous breathing) |
| Pinsker 2007 [ | NA | NA | Propofol (dosage NK) | No medication | Propofol if required | No | No | Oxygen via nasal cannula (spontaneous breathing) |
| Rajan 2013 [ | Propofol + dexmedetomidine | Initial: Propofol 50–250 μg kg-1 min-1 and dexmedetomidine 1 μg kg-1 loading dose (in 10–15 min.). Thereafter Propofol 50–250 μg kg-1 min-1 and dexmedetomidine 0.4–0.7 μg kg-1 hr-1. | NA | Cessation propofol, reduction/ cessation of dexmedetomidine and 25–50μg fentanyl, if required for pain (fentanyl mean ± SD 169.8 μg ± 80.32μg) | NK | No | No | 2-8l min-1 oxygen via nasal airway and nasal cannula. (spontaneous breathing) |
| Rughani 2011 [ | Propofol + fentanyl + midazolam | Initial: propofol 0.1–0.3mg kg-1, then continuously 0.025–0.05 mg kg-1 min-1. Fentanyl 50–200μg and midazolam 1-2mg titrated as needed. | NA | No medication | Resuming propofol induction and continuous infusion, with fentanyl and midazolam as needed. | No | No | Spontaneous breathing, oral airway only described for 5 patients |
| Sacko 2010 [ | NA | NA | Continuous propofol (1–3 mg kg-1 h-1) and fentanyl 1–3 μg kg-1 hr-1 or remifentanil 0.01–0.25 μg kg-1 hr-1 | Cessation propofol only | Resuming propofol infusion | No | No | 6l min-1 oxygen via face mask |
| Sanus 2015 [ | Propofol + dexmedetomidine + remifentanil | Dexmedetomidine 0.02–0.5 μg kg-1 hr-1, propofol 30–180 μg kg-1 hr-1 and remifentanil 0.03–0.09 μg kg-1 hr-1 are used. BIS target 60–80. | NA | BIS target >80, no further information | NK | No | BIS | Nasopharyngeal airway (spontaneous breathing) |
| See 2007 [ | NA | NA | Fentanyl bolus 25–50μg, remifentanil 0.005 to 0.02 3 μg kg-1 min-1, propofol (n = 15), | No medication | NK | No | No | Nasal cannula (spontaneous breathing) |
| Serletis 2007 [ | NA | NA | Propofol, midazolam and fentanyl, exact dosage NK | NK | Propofol, midazolam and fentanyl, exact dosage NK | No | No | Oxygen via nasal cannula, (spontaneous breathing) |
| Shen 2013 [ | TCI-TIVA (propofol + remifentanil) + dexmedetomidine | Initial in both groups: propofol-TCI Marsh model, Cp 4 μg ml-1, cis-atracurium 0.2 mg kg-1 and remifentanil-TCI, Minto model, 3ng ml-1 (Cp). Thereafter in both groups: remifentanil 2ng ml-1 (Cp) and cis-atracurium 0.1 mg kg-1 h-1 and aim RE 60–80. Propofol group: propofol 1–4 μg ml-1 (Cp). Dexmedetomidine group: propofol discontinued and dexmedetomidine loaded with 1μg kg-1, followed by 0.2–0.7 μg kg-1 h-1. | NA | Both groups: Aim RE >80. Remifentanil 0.5 ng ml-1 (Cp). Propofol group: propofol discontinued and normal saline (placebo) 5 ml h-1 was infused. Dexmedetomidine group: dexmedetomidine 0.2 μg kg-1 h-1. | Only re-induction of anaesthesia is mentioned. | Cis-atracurium 0.2 mg kg-1 and continuous infusion of 0.1 mg kg-1 h-1 | RE | Endotracheal tube, controlled ventilation, FiO2 = 1.0. |
| Shinoura 2013 [ | Propofol, dexmedetomidine, or remifentanil | NK | NA | Nothing | Propofol and replacement of LMA | NK | NK | LMA at the beginning and the end, ventilation mode NK |
| Sinha 2007 [ | NA | NA | 1.) Fentanyl 25–50 μg before application of RSNB 2.) Induction with propofol 1–2 mg kg-1, fentanyl 0.5–1.0 μg kg-1, and midazolam 1–2 mg i.v. 3.) Continuous fentanyl 0.5–2 μg kg-1 h-1 and propofol 1–5 mg kg-1 h-1. Aim BIS >60. 4.) Diclofenac 50–75 mg/ tramadol 50–100 mg if needed | NK | NK | No | BIS (n = 16) | Oxygen via nasal cannula 2–4 l min-1, continuous positive airway pressure was delivered through nasal trumpet in 1 patient |
| Sokhal 2015 [ | NA | NA | 1.) Fentanyl and propofol until 2010 (n = 44), titrated as bolus/ continuous (fentanyl 0.25–1.5 μg kg-1 h-1, propofol 25–200 μg kg-1 min-1. 2.) Since 2010: Dexmedetomidine solely (n = 6) 1 μg kg-1 loading dose, followed by 0.2–0.7 μg kg-1 h-1, 3.) along with titrated doses of fentanyl (n = 3), 4.) along with titrated doses of propofol and fentanyl (n = 1). Aim RE/ BIS: 60–80 | Cessation of propofol, but continued fentanyl and dexmedetomidine | NK | No | RE/ BIS (n = 14) | Oxygen mask or nasal cannula (spontaneous breathing) |
| Souter 2007 [ | SAS (n = 2) Propofol, fentanyl, dexmedetomidine | Induction with 3 mg kg-1 propofol, thereafter 100–200 μg kg-1 min-1 and fentanyl 25 μg boluses. | 1. Only dexmedetomidine 01.5–0.7 μg kg-1 h-1 (n = 3), 2. Additional propofol 150–200 μg kg-1 min-1 for the beginning of surgery (n = 1). Fentanyl 25–50μg was additionally applied in 3 patients. | SAS (n = 2): cessation of propofol, removal of LMA and start of dexmedetomidine 0.1–0.3 μg kg-1 h-1, MAC (n = 4) continuous dexmedetomidine. | SAS (n = 2) reinduction of propofol and reinsertion of LMA. | No | Only clinical with the (OAA/S) score | SAS (n = 2): LMA; MAC (n = 4) oxygen 2–4 l min-1 nasal cannula (spontaneous breathing) |
| Wrede 2011 [ | NA | NA | Combination of midazolam, dehydrobenzperidol and piritramide | NK | NK | No | No | NK |
| Zhang 2008 [ | NA | NA | TIVA-TCI with propofol (Marsh’s Model), and sufentanil (Bovill’s model) or remifentanil (Minto’s model) | NK | NK | No | BIS | Nasopharyngeal airway (spontaneous breathing) |
± SD, and standard deviation; Cp, target plasma concentration; n =, specified number of patients; NA, not applicable; NK, not known as not reported; OAA/S, observer Assessment of alertness/ sedation score; RE, response entropy index; SD, standard deviation; TCI, target-controlled infusion.
Intraoperative characteristics and adverse events.
| Study | Duration surgery in min., mean ± SD [range] | Duration awake phase in min., mean [range]/ ± SD | AC failure | Conversion into GA | Intraoperative seizures /history of seizures in these patients | Intraoperative hypoxia | intraoperative hypertension (>20%deviation from baseline) | Nausea and/or vomiting |
|---|---|---|---|---|---|---|---|---|
| Abdou 2010 [ | 168.8 ± 19.4; [150–215] | NK | NK | 0 | 2/NK | 1 | 2 | 2 (postoperative), 1 (intraoperative) |
| Ali 2009 [ | 173 ± 13 | NK | 0 | 0 | 2/NK | 5 | NK | 1 (postoperative), 0 (intraoperative) |
| Amorim 2008 [ | NK | NK | 0 | 0 | 2 (dex group)/2 | 0 | NK | NK |
| Andersen 2010 [ | NK | 166 [75–320] | 3 (LMA leakage n = 1, respiratory insufficiency n = 1, intraoperative bleeding n = 1) | 3 (LMA leakage n = 1, respiratory insufficiency n = 1, intraoperative bleeding n = 1) | 12/NK | 1 | 1 | 4/2 |
| Beez 2013 [ | NK | 76 [20–137] | 0 | 0 | 14/12 | NK, but no anaesthesiological complication reported | NK, but no anaesthesiological complication reported | NK |
| Bilotta 2014 [ | NK | NK | 0 | 0 | 3 | 0 | NK | NK |
| Boetto 2015 [ | NK | NK | 0 | 0 | 13/12 | NK | NK | NK |
| Cai 2013 [ | [450–780] | NK | 0 | 0 | 0 | 0 | NK | NK |
| Chacko 2013 [ | NK | NK | 1 (restlessness) | 0 | 3/NK | 0 | NK | NK |
| Chaki 2014 [ | NK | 96 ± 45 | 1 (pain) | 1 (pain) | 0 | 0 | 0 | NK |
| Conte 2013 [ | median 403 [259–562] | NK | 0 | 0 | 4/NK | NK | 1 | NK |
| Deras 2012 [ | NK | 98 ± 27 | 0 | 0 | 0/NK | 0 | 0 | 3 (intraoperative) |
| Garavaglia 2014 [ | median 210 [180–540] | NK | 0 | 0 | 0 | 0 | 0 | NK |
| Gonen 2014 [ | NK | NK | 0 | 0 | 28/NK | NK | NK | NK |
| Grossman 2007 [ | 202 ± 45 | NK | NK | NK | NK | NK | 5 | 0 |
| Grossman 2013 [ | NK | NK | NK | 0 | 20 (18 young and 2 elderly)/NK | NK | NK | NK |
| Gupta 2007 [ | 196 | NK | 1 (brain bulge) | 1 (brain bulge) | 1/NK | NK | NK | NK |
| Hansen 2013 [ | 217±45 [105–295] | NK | 1 (seizure) | 1 (seizure) | 8/NK | 3 | 22 (>10% deviation) | 1 (postoperative) |
| Hervey-Jumper 2015 [ | NK | NK | 3 (seizures) | 0 | 20/19 | NK | NK | NK |
| Ilmberger 2008 [ | NK | NK | 0 | 0 | 7/69 | NK | NK | NK |
| Jadavji-Mithani 2015 [ | NK | NK | 0 | 0 | 2/NK | 1 | NK | 2 (intraoperative) |
| Kim 2009 [ | NK | NK | 1 (agitation/ pain) | 8 (agitation/ pain) | 27/22 | NK | NK | NK |
| Li 2015 [ | NK | NK | 0 | NK | 7/NK | NK | NK | NK |
| Lobo 2007 [ | NK | NK | 0 | 0 | 1/NK | 1 | 0 | NK |
| Low 2007 [ | 165 [85–275] | NK | 0 | 0 | NK | 1 | 3 | NK |
| McNicholas 2014 [ | NK | NK | 0 | NK | NK | NK | NK | NK |
| Nossek 2013 [ | NK | NK | 27 (seizures n = 5, severe restlessness n = 8, acute brain oedema n = 1, severe dysphasia n = 11, somnolence n = 2). | 9 (seizures n = 5, severe restlessness n = 3, acute brain oedema n = 1). | 49 /NK | NK | NK | NK |
| Nossek 2013 [ | NK | NK | 37 (intractable seizures n = 11), dysphasia, restlessness, and somnolence n = 26). | 7 (seizures) | 60/37 | NK | NK | NK |
| Olsen 2008 [ | NK | 165 [75–245] | 2 (LMA leakage n = 1, intraoperative brain swelling n = 1) | 2 (LMA leakage n = 1, intraoperative brain swelling n = 1) | 4/NK | 0 | 1 | 1/1 |
| Ouyang 2013 [ | Malignant group 211.6±63.6, benign group 213.9±75.8 | NK | NK | NK | NK | NK | NK | 124 (benign group n = 39, malignant group n = 85) postoperative |
| Ouyang 2013 [ | Midline shift 201.3±54.1, no midline shift 242.7±87.4 | NK | NK | NK | NK | NK | NK | 113 (midline shift n = 84, no midline shift n = 29) postoperative |
| Pereira 2008 [ | NK | NK | 2 (Intubation group B > 8/2004) | 2 (Intubation group B > 8/2004) | 16 (n = 2 group A, <8/2004; n = 14 group B >8/2004)/ NK | 2 (Group B >8/2004) | NK | NK |
| Peruzzi 2011 [ | NK | NK | 0 | 0 | NK/4 | NK | NK | NK |
| Pinsker 2007 [ | NK | NK | 0 | 0 | 0/NK | NK | NK | NK |
| Rajan 2013 [ | NK | NK | 1 (hypoxia SpO2 <90%) | 1 (hypoxia SpO2 <90%) | 2/NK | 26 | 28 (need for antihypertensive medication) | 5 (postoperative) |
| Rughani 2011 [ | 159, range [75–315] | NK | 1 (respiratory insufficiency) | 1 (respiratory insufficiency) | 3/1 | NK | NK | 0 |
| Sacko 2010 [ | 135 | NK | 0 | 0 | 14/NK | 0 | 0 | NK |
| Sanus 2015 [ | NK | NK | 0 | 0 | 0 | 0 | 0 | NK |
| See 2007 [ | median 240 [120–420] | NK | 0 | 0 | 0 | 3 | 4 | 1 (intraoperative), 2 (postoperative) |
| Serletis 2007 [ | NK | NK | 2 (seizures) | 2 (seizures) | 25/NK | NK | NK | NK |
| Shen 2013 [ | Dexmedetomidine 271.9±20.0, propofol 254.5±29.4 | Dexmedetomidine 31.7±7.0, propofol 29.6±5.9 | 0 | 0 | NK | 1 (propofol group) | 3 (dexmedetomidine 1, propofol 2) | 2 (dexmedetomidine n = 1, propofol n = 1) intraoperative |
| Shinoura 2013 [ | NK | NK | 6 (n = 2 air embolism, n = 1 seizure, n = 1 motor neglect, n = 1 somnolence, n = 1 no wake up after GA) | 6 (n = 2 air embolism, n = 1 seizure, n = 1 motor neglect, n = 1 somnolence, n = 1 no wake up after GA) | 1/NK | NK | NK | NK |
| Sinha 2007 [ | 376.7±105.6 [240–480] | NK | 1 (restlessness) | 2 (restlessness and hypoxia) | 4 (no BIS n = 3, BIS n = 1) / NK | 2 | 8 | 8 (postoperative) |
| Sokhal 2015 [ | 268±45,7 [165–390] | NK | 1 (brain bulge) | 1 (brain bulge) | 5/5 (propofol n = 2, dexmedetomidine n = 3) | 4 (propofol n = 3, dexmedetomidine n = 1) | 9 (propofol) | 0 (intraoperative) |
| Souter 2007 [ | NK | NK | 0 | 0 | 1(SAS group)/6 | 0 | 1 | NK |
| Wrede 2011 [ | NK | NK | 0 | 0 | NK | NK | NK | NK |
| Zhang 2008 [ | NK | NK | 6 (n = 4 brain bulge, n = 2 somnolence) | 0 | 2/NK | 0 | NK | NK |
AC, awake craniotomy; LMA, laryngeal mask airway; min., minutes; n =, specified number of patients; NK, not known; PON(V), postoperative nausea (and vomiting); SD, standard deviation; SpO2, peripheral oxygen saturation. Data are presented as numbers of patients, or mean ± standard deviation or [range].
Patient outcomes.
| Study | New neurological dysfunction | Persistent neurological dysfunction >6months if not otherwise stated | Mortality | Postoperative intracranial haematoma | Tumour total resection | Length of hospital stay in days (mean and standard deviation, if not otherwise stated) |
|---|---|---|---|---|---|---|
| Abdou 2010 [ | NK | NK | 0 | NK | NK | 3.1 ± 1.1, range [1–5] |
| Ali 2009 [ | 1 | 0 | 0 | NK | 8 | 3.8 ± 4.15 |
| Amorim 2008 [ | 2 | 1 | 0 | 0 | 8 | NK |
| Andersen 2010 [ | NK | NK | 0 | NK | NK | NK |
| Beez 2013 [ | NK | NK | 0 | NK | NK | NK |
| Bilotta 2014 [ | 7 (only for language described) | 3 (only for language described) | 0 | NK | 13 | NK |
| Boetto 2015 [ | NK | 0 | 0 | 0 | NK | NK |
| Cai 2013 [ | 4 | 0 | 0 | NK | NK | NK |
| Chacko 2013 [ | 8 | NK after 6 months but after 40 months only 3 of the new remained | 1 | NK | NK for all patients | NK |
| Chaki 2014 [ | NK | NK | 0 | NK | NK | NK |
| Conte 2013 [ | NK | NK | NK | NK | NK | NK |
| Deras 2012 [ | NK | NK | 0 | 3 | NK | NK |
| Garavaglia 2014 [ | 0 | 0 | 0 | 0 | NK | NK |
| Gonen 2014 [ | 17 | 0 | 0 | NK | 89 | 4,96±4,69 of all 4 groups |
| Grossman 2007 [ | NK | NK | 1 (<12h) | NK | NK | NK |
| Grossman 2013 [ | 92 (n = 71 young+n = 21 elderly) | NK | 5 (n = 2 young+n = 3 elderly) | 12 (9 young + 3 elderly) | 343 (n = 272 young + n = 71 elderly) | 6.6 ± 7.5 elderly vs. 4.9 ± 6.3 young |
| Gupta 2007 [ | NK | NK | NK | NK | 10 | 5.69±5.3 range [2–28] |
| Hansen 2013 [ | 8 | NK | 0 | NK | 29 | NK |
| Hervey-Jumper 2015 [ | 58 | 16 (3 months) | 0 | 3 | NK | Median 3, range [2–20] |
| Ilmberger 2008 [ | 41 | 14 | 0 | NK | 74 | NK |
| Jadavji-Mithani 2015 [ | NK | NK | 0 | NK | NK | NK |
| Kim 2009 [ | 74 | 34 (1 month) | 0 | NK | 199 | 4 [3–53] |
| Li 2015 [ | 49 | 1 | 0 | NK | 53 | NK |
| Lobo 2007 [ | NK | NK | 0 | NK | NK | NK |
| Low 2007 [ | 6 | 1 | 0 | 1 | 11 | 5.5 [11–16] for n = 16 patients |
| McNicholas 2014 [ | 7 | 0 | 0 | NK | NK | NK |
| Nossek 2013 [ | 30 (n = 6 failure group + n = 24 not failure group) (only speech deterioration assessed) | 13 (n = 4 failure group + n = 9 not failure group) (only speech deterioration assessed) | 1 | 20 (n = 4 failure group + n = 16 not failure group) | 343 | The length of hospital stay was significantly longer for the failure group than the successful group (8.0 ± 10.1 vs. 4.9 ± 6.2). |
| Nossek 2013 [ | 54 (n = 12 seizure + n = 42 nonseizure) | 0 | 1 (non-seizure) | 21 (n = 3 seizure + n = 18 non-seizure) | 379 | 4±3 seizure, 3±3 non-seizure |
| Olsen 2008 [ | NK | NK | 0 | NK | NK | NK |
| Ouyang 2013 [ | NK | NK | 0 | 2 | NK | NK |
| Ouyang 2013 [ | NK | NK | 0 | 2 | NK | NK |
| Pereira 2008 [ | NK | 23 (n = 3 worsening of pre-existing dysfunction at 6 month in group A <8/2004; n = 20 worsening of pre-existing dysfunction at 6 month in group B >8/2004) | 1 | 2 (n = 1 group A (<8/2004); n = 1 group B (>8/2004)) | 9 (n = 4 group A (<8/2004); n = 5 group B (>8/2004)) | NK |
| Peruzzi 2011 [ | 4 | NK | 0 | NK | 22 | 3.5 range [3–5] |
| Pinsker 2007 [ | 14 | 8 (3 months) | 0 | NK | 40 | NK |
| Rajan 2013 [ | NK | NK | 0 | NK | NK | 3±3.4 |
| Rughani 2011 [ | 6 | 2 (1 month) | 0 | NK | 20 | 3.7 range [2–8] |
| Sacko 2010 [ | 7 | NK | 0 | 4 | 80 | median 4.5 |
| Sanus 2015 [ | 4 | 0 | 0 | 0 | 20 | median 5 |
| See 2007 [ | 5 | 1 (after discharge) | 0 | 0 | NK | median 9 [3–77] |
| Serletis 2007 [ | 20 | 12 | NK | NK | NK | NK |
| Shen 2013 [ | NK | NK | 0 | NK | NK | NK |
| Shinoura 2013 [ | 8 | 3 (1 month) | 0 | NK | 54 | NK |
| Sinha 2007 [ | 10 | 0 | 0 | NK | NK | 13.3±4.2 |
| Sokhal 2015 [ | 14 | 12 | 0 | 1 | NK | 7±5 [3–30] |
| Souter 2007 [ | NK | NK | 0 | NK | NK | NK |
| Wrede 2011 [ | 2 | NK | 0 | NK | NK | NK |
| Zhang 2008 [ | 13 (n = 6 group 1; n = 1 group 2; n = 6) | 7 (n = 2 group 1; n = 1 group 2; n = 4 group 3) | 0 | 1 | 14 | NK |
n =, specified number of patients; NK, not known; vs., versus.
Fig 2Forrest plot of awake craniotomy failure.
The summary value is an overall estimate from a random-effect model. The vertical dotted line shows an overall estimate of outcome proportion (based on the meta-analysis) disregarding grouping by technique. Of note, Souter et al. [60] have used both anaesthesia techniques.
Fig 3Forrest plot of conversion into general anaesthesia.
The summary value is an overall estimate from a random-effect model. The vertical dotted line shows an overall estimate of outcome proportion (based on the meta-analysis) disregarding grouping by technique. Of note, Souter et al. [60] have used both anaesthesia techniques. GA, general anaesthesia.
Fig 4Forrest plot of intraoperative seizures.
The summary value is an overall estimate from a random-effect model. The vertical dotted line shows an overall estimate of outcome proportion (based on the meta-analysis) disregarding grouping by technique. Of note, Souter et al. [60] have used both anaesthesia techniques.
Fig 5Forrest plot of new neurological dysfunction.
The summary value is an overall estimate from a random-effect model. The vertical dotted line shows an overall estimate of outcome proportion (based on the meta-analysis) disregarding grouping by technique. Neurol. dysf., neurological dysfunction.